Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091663 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,000
- Enrollment target
NCT00091663: Completed Phase 3 study, sponsored by Genentech.
NCT00091663 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 5,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (548% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091663, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,000 participants
- Enrollment target
Study Summary
This is a Phase IIIb, multicenter, open-label trial of daily oral Tarceva in patients with advanced (inoperable Stage IIIb or IV) NSCLC who have progressed following standard chemotherapy treatment.
Interventions
- DRUG Tarceva (erlotinib HCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
What the finished NCT00091663 record still lists
NCT00091663 is an interventional study that assigns participants to a tested intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (548% higher).
The record links to 0 conditions, and to 1 intervention - of which Tarceva (erlotinib HCl) is the first listed.
NCT00091663 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00091663 about?
NCT00091663 is a clinical study titled "A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". This is a Phase IIIb, multicenter, open-label trial of daily oral Tarceva in patients with advanced (inoperable Stage IIIb or IV) NSCLC who have progressed following standard chemotherapy treatment.
What is the current status of trial NCT00091663?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,000 participants. The study started on 2004-08. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00091663?
The interventions under investigation include: Tarceva (erlotinib HCl) (DRUG).
Who is sponsoring clinical trial NCT00091663?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00091663's enrollment target sits among peer trials
5,000 49th of 2000 higher than 1,949 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia